The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 09, 2025

Filed:

Sep. 13, 2022
Applicant:

Jiangsu Kanion Pharmaceutical Co., Ltd, Jiangsu, CN;

Inventors:

Wei Xiao, Jiangsu, CN;

Haibo Li, Jiangsu, CN;

Guiping Li, Jiangsu, CN;

Tuanjie Wang, Jiangsu, CN;

Shasha Gu, Jiangsu, CN;

Xu Li, Jiangsu, CN;

Quanchang Zhang, Jiangsu, CN;

Liang Cao, Jiangsu, CN;

Wenjun Liu, Jiangsu, CN;

Chenfeng Zhang, Jiangsu, CN;

Zhenzhong Wang, Jiangsu, CN;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 36/00 (2006.01); A61K 33/06 (2006.01); A61K 35/32 (2015.01); A61K 35/413 (2015.01); A61K 36/484 (2006.01); A61K 36/539 (2006.01); A61K 36/708 (2006.01); A61K 36/8966 (2006.01); A61P 11/14 (2006.01); A61P 29/00 (2006.01); A61P 31/14 (2006.01);
U.S. Cl.
CPC ...
A61K 35/413 (2013.01); A61K 33/06 (2013.01); A61K 35/32 (2013.01); A61K 36/484 (2013.01); A61K 36/539 (2013.01); A61K 36/708 (2013.01); A61K 36/8966 (2013.01); A61P 11/14 (2018.01); A61P 29/00 (2018.01); A61P 31/14 (2018.01);
Abstract

The disclosure relates to a traditional Chinese medicine composition, comprising active ingredients derived fromoretartifactus and Lapis Chloriti, the said active ingredients comprise in parts by weight: at least 1600 parts of amino acids; at least 120 parts of gallic acid; at least 130 parts of liquiritin; at least 20 parts of liquiritigenin; at least 400 parts of baicalin; at least 40 parts of oroxyloside; at least 120 parts of wogonoside; at least 280 parts of glycyrrhizic acid; at least 12 parts of chrysin-7-O-β-D-glucoronic acid; at least 50 parts of aloe-emodin-8-O-β-D-glucopyranoside; at least 30 parts of chrysophanol-1-O-β-D-glucopyranoside; at least 45 parts of chrysophanol-8-O-β-D-glucopyranoside; at least 260 parts of hyodeoxycholic acid; at least 150 parts of cholic acid. The traditional Chinese medicine composition in the present invention possess antipyretic, anti-inflammatory and antitussive effects.


Find Patent Forward Citations

Loading…